Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
← catalyst calendarNCT06799247 · readout in 103 d
Sponsored by Cartesian Therapeutics (industry) · RNAC — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
100estimated
Sites
34
Countries
Canada, Italy, Poland +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-06 | actual | When the study began enrolling |
| Primary completion | 2026-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myasthaenia Gravis
Interventions
- Biological: Decartes-08
- Other: Placebo Drug
Primary outcome
what the primary-completion date above is the date OFMyasthenia Gravis Activities of Daily Living (MG-ADL)
measured assessment at 4 months of study
Permalink · RNAC's whole pipeline · Catalyst calendar · Every registered study · What changed